Page 30 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association ... Merus N.V.March 10, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Merus will present preclinical data from our zenocutuzumab and...

(2) UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Merus will present preclinical data from our zenocutuzumab and MCLA-129 programs in three poster presentations at the American Association for Cancer Research 2021 Annual Meeting being held virtually for two weeks, April 10-15, 2021 and May 17-21, 2021. E-Poster Presentation: Title: The HER2×HER3 bi-specific antibody zenocutuzumab...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in...

Merus N.V. Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonic...

Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment News provided by Share this article SAN CARLOS, Calif., Jan. 12, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the American Society of Clinical Oncology's 2021 ...